Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: Excellent feasibility and low incidence of treatment-related toxicity

Bone Marrow Transplantation

Volumn 19, Issue 12, 1997, Pages 1169-1173

  Bertz, H ^a   Potthoff, K ^a   Mertelsmann, R ^a   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ATG; Busulfan cyclophosphamide; Feasibility; Mismatch transplants; VUD BMT

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HEPARIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG TOXICITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; ORGAN DONOR; PRIORITY JOURNAL;

EID: 0030824872     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700823     Document Type: Article

References (33)

1. Hansen JA, Clift RA, Thomas ED et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. New Engl J Med 1980; 303: 585-591.
2. Appelbaum FR. The influence of total dose, fractionation, dose rate and distribution of total body irradiation on bone marrow transplantation. Semin Oncol 1993; 20 (Suppl): 3-10.
3. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1351.
4. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
5. Hassan M, Öberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
6. Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80: 1646-1658.
7. Hassan M, Ljungman P. Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
8. Mehta J, Powles RL, Mitchell P et al. Graft failure after bone marrow trasnplantation from unrelated donors using busulphan and cyclophosphamide for conditioning. Bone Marrow Transplant 1994; 13: 583-587.
9. Ballester OF, Agaliotis DP, Hiemenz JW et al. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Bone Marrow Transplant 1996; 18: 9-14.
10. Chao NJ, Stein AS, Long GD et al. Busulfan/etoposide -initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia. Blood 1993; 81: 319-323.
11. Linker CA, Damon LE. Ries CA et al. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol 1993; 20: 40-48.
12. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan vs cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Grafts. Blood 1995; 85: 2263-2268.
13. Geller RB, Sarai R, Piantadosi S et al. Allogeneic bone marrow transplantation after high-dose busulphan and cyclophosphamide in patients with acute nonlymphoblastic leukemia. Blood 1989; 73: 2209-2218.
14. Ratanatharathorn V, Karanes C, Lum LG et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194-2199.
15. O'Donnell MR, Long GD, Parker PM et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13: 2973-2979.
16. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
17. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan vs cytoxan-total body irradiation as a preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
18. Gajewski J, Sahebi F, Crilley P et al. Use of the Ohio state busulfan/cyclophosphamide regimen in recipients of matched unrelated donor transplants. Bone Marrow Transplant 1995; 15 (Suppl. 1): 88-91.
19. Klein JL, Avalos BR, Belt P et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant 1996; 17: 479-483.
20. Spencer A, Szydia RM, Brookes PA et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995; 86: 3590-3597.
21. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease of bone marrow transplantation by continous infusion of low-dose heparin, a prospective randomized trial. Blood 1992; 79: 2834-2837.
22. Warkentin PI, Hilden JH, Kersey JH et al. Transplantation of major ABO-incompatible bone marrow deplete of red cells by hydroxyethyl starch. Vox Sang 1985; 48: 89-104.
23. Santos GW, Tutschka PJ, Brookmeyer R et al. Cyclosporine plus methylprednisolone vs cyclophosphamide and methylprednisolone as prophylaxis for graft-versus-host diesease: a randomized double blind study in patients undergoing allogeneic transplantation. Clin Transplant 1987; 1: 21-28.
24. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease New Engl J Med 1993; 329: 1225-1230.
25. Sahebi F, Copelan E, Crilley P et al. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (Bu-Cy) for the preparative regimen. Bone Marrow Transplant 1996; 17: 685-689.
26. deMagalhaes-Silverman M, Bloom EJ, Donnenberg A et al. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 329-333.
27. Topolsky D, Crilley P, Styler MJ et al. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy-only conditioning regimen. Low incidence of failed engraftment and severe acute GVHD. Bone Marrow Transplant 1996; 17: 549-554.
28. Ratanatharathorn V, Karanes C, Lum LG et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 1992; 9: 49-55.
29. Morgan M, Dodds A, Atkinson K et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Hematol 1991; 77: 529-534.
30. Ehninger G, Schuler U, Renner U et al. Use of a water-soluble busulfan formulation - pharmacokinetic studies in a canine model. Blood 1995; 85: 3247-3249.
31. Martino R, Badell I, Brunet S et al. High-dose busulfan and melphalan before bone marrow transplantation for acute non-lymphoblastic leukemia. Bone Marrow Transplant 1995; 16: 209-212.
32. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
33. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.